What is Tirzepatide (LY3298176)?
Tirzepatide, development code LY3298176, is a synthetic 39-amino-acid peptide engineered as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. It is built on a modified GIP backbone with a fatty-diacid side chain. It is supplied as a lyophilized powder for in-vitro laboratory research use only.
Tirzepatide research
Published work on Tirzepatide is qualitative in the framing below. Each item describes the focus of the research itself, not an outcome for any person.
- Dual-receptor pharmacology. Research has characterized tirzepatide binding and signaling at the GIP and GLP-1 receptors.
- Glycemic-endpoint research. Tirzepatide has been the subject of clinical research programs examining glycemic measures in study populations.
- Body-weight regulation research. Studies have explored body-weight endpoints in research populations.
- Comparative research. Investigations have compared dual-receptor agonism with single-receptor GLP-1 agonists.
Tirzepatide specifications
| CAS Number | 2023788-19-2 |
|---|---|
| Synonyms | LY3298176 |
| Molecular Formula | Provided on batch COA |
| Molecular Weight | Provided on batch COA |
| Sequence | 39 amino acids (provided on batch COA) |
| Purity | ≥99% by HPLC |
| Physical Form | Lyophilized powder |
| Solubility | Soluble in bacteriostatic or sterile water |
| Storage | Store lyophilized at -20°C; protect from light |
| Shelf Life | 24+ months lyophilized at -20°C |
| Presentation | 20 mg per vial |
Tirzepatide reconstitution & storage
Store the sealed lyophilized vial at -20°C. Reconstitute with bacteriostatic or sterile water by directing the stream against the vial wall; do not shake. After reconstitution, store refrigerated at 2 to 8°C and use within the period indicated on the batch COA. For laboratory research handling only.
Tirzepatide certificate of analysis (COA)
A batch-specific Certificate of Analysis accompanies every order, as it does for all peptides for laboratory research from PeptideX1. The COA documents identity and purity by HPLC for the lot you receive, along with the molecular data listed as provided on batch COA above. Third-party analytical reports are available on request.
Tirzepatide research references
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021. PubMed
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022. PubMed
- PubChem compound record for Tirzepatide. National Library of Medicine. PubChem
Tirzepatide FAQ
What is Tirzepatide (LY3298176)?
Tirzepatide, development code LY3298176, is a synthetic 39-amino-acid peptide engineered as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. It is built on a modified GIP backbone with a fatty-diacid side chain. It is supplied as a lyophilized powder for in-vitro laboratory research use only.
What purity does PeptideX1 Tirzepatide meet?
Each batch is ≥99% purity by HPLC, verified per batch on the accompanying Certificate of Analysis.
Is a Certificate of Analysis included?
Yes. A batch-specific Certificate of Analysis is included with every order.
How is it shipped and stored?
It ships lyophilized, sealed and desiccated. Store the sealed vial at -20°C and protect it from light.
How does tirzepatide differ from GLP-3 R?
Tirzepatide is a dual agonist acting at the GIP and GLP-1 receptors. GLP-3 R is a triple agonist that adds activity at the glucagon receptor. Both are offered strictly as research materials and are not for human use or weight management.
Is this product for human use?
No. It is sold strictly for in-vitro laboratory research use only. It is not for human or veterinary use.